MBHS said that the new MoU covers the regulatory certification required by the Russian regulator, regional sales, marketing and distribution of SkinScan 650, SCS’s non-invasive, point-of-care system to detect and identify different types of skin cancers.
The SkinScan 650 is a medical device that enables physicians to diagnose skin cancer at an earlier, more curable stage, which reduces the number of biopsies, lower treatment costs, and improve quality of life.
Yossi Biderman, CEO of mBeach, said: “This MoU is an important element of our growth strategy for this region. Our product, though still a prototype, will be ideally suited, once the industrial prototype is approved by the Russian regulator, to meet the growing demand for better cancer detection.
“We are very excited at the potential of this market and see this MoU as a stepping stone to entering additional, attractive markets around the world.”
SCS is a medical device company developing and commercialising a proprietary imaging system for the early detection and diagnosis of skin cancer.
